A pharmaceutical company that pioneered peptide pharmaceutical products, and a leader in reproductive medicine and women’s health, gastroenterology, and urology, had recently made the strategic decision to increase its in-licensing activities in order to supplement its internal pipeline development. While the company has an innovation sourcing team with coverage in Europe, China, and US west coast, it was recognized that a fresh pair of ‘boots on the ground’ in the US would support in-licensing opportunities. Alacrita was therefore engaged to conduct scouting activities, focusing on therapeutic assets and biomarkers in urology, hepatology, gastrointestinal disorders (particularly inflammatory bowel disease) and reproductive and women’s health. Alacrita scouted for assets significantly differentiated from existing agents (first-in-class, innovative assets), all the way from discovery phase of development to Phase I clinical development.
Alacrita’s activities included regular attendance at meetings and conferences which were likely to attract new biotech companies in early preclinical or clinical stage of development; scanning of new and recent literature to identify emerging opportunities; searches of grants, deals, and pipeline databases; outreach and networking with biotech and pharma companies, industry contacts, big pharma and licensing professionals and technology transfer offices. We worked closely with the client’s team to identify important targets and pathways of interest and took an iterative approach to adjust our search criteria, such that they align with client’s evolving interests throughout the engagement. We tracked opportunities in a document that was updated and shared on a weekly basis. Opportunities that Alacrita identified as appropriate for the incubator were delivered on a rolling basis.Back